{
    "symbol": "NKTR",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-03 23:15:27",
    "content": " This Phase 2/3 trial will be a randomized, double-blind, placebo-controlled study comparing NKTR-255 versus placebo and relapsed or refractory patients being treated with CAR-T cells. Your line is open. One moment for our next question, please. Your line is open. One moment for our next question, please. Your line is open. One moment for our next question, please. Your line is open. One moment for our next question, please. Your line is open. Your line is open. Your line is open."
}